Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 26, 2023

BUY
$99.42 - $131.97 $4.09 Million - $5.43 Million
41,112 Added 36.51%
153,719 $0
Q3 2022

Oct 28, 2022

BUY
$84.03 - $110.23 $295,785 - $388,009
3,520 Added 3.23%
112,607 $12 Million
Q2 2022

Aug 02, 2022

BUY
$78.08 - $117.61 $1.53 Million - $2.31 Million
19,610 Added 21.92%
109,087 $9.59 Million
Q1 2022

Apr 27, 2022

BUY
$102.18 - $135.75 $207,118 - $275,165
2,027 Added 2.32%
89,477 $10.5 Million
Q4 2021

Feb 18, 2022

BUY
$127.1 - $169.66 $2.47 Million - $3.29 Million
19,411 Added 28.53%
87,450 $11.8 Million
Q3 2021

Nov 22, 2021

SELL
$112.67 - $176.92 $476,819 - $748,725
-4,232 Reduced 5.86%
68,039 $10.8 Million
Q2 2021

Aug 26, 2021

BUY
$121.62 - $145.29 $3.43 Million - $4.09 Million
28,180 Added 63.91%
72,271 $9.51 Million
Q1 2021

Apr 28, 2021

BUY
$124.92 - $173.33 $1.89 Million - $2.62 Million
15,143 Added 52.31%
44,091 $5.68 Million
Q4 2020

Jan 28, 2021

BUY
$151.2 - $182.76 $1.83 Million - $2.22 Million
12,125 Added 72.07%
28,948 $4.83 Million
Q3 2020

Oct 30, 2020

BUY
$134.29 - $154.32 $217,146 - $249,535
1,617 Added 10.63%
16,823 $2.6 Million
Q2 2020

Jul 31, 2020

BUY
$110.87 - $156.01 $124,507 - $175,199
1,123 Added 7.97%
15,206 $2.25 Million
Q1 2020

May 01, 2020

BUY
$97.01 - $145.11 $1.13 Million - $1.69 Million
11,671 Added 483.87%
14,083 $1.59 Million
Q4 2019

Feb 07, 2020

BUY
$91.45 - $139.12 $4,115 - $6,260
45 Added 1.9%
2,412 $335,000
Q3 2019

Oct 31, 2019

SELL
$95.8 - $118.9 $8,909 - $11,057
-93 Reduced 3.78%
2,367 $227,000
Q2 2019

Aug 02, 2019

BUY
$107.11 - $132.09 $19,172 - $23,644
179 Added 7.85%
2,460 $0
Q1 2019

May 02, 2019

BUY
$62.15 - $129.99 $141,764 - $296,507
2,281 New
2,281 $0

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.